SCHEMBL6931040

SCHEMBL6931040

CCP(=O)(ON(Nc1ccc(C#N)cc1OC)c1ccccc1Br)ON(Nc1ccc(C#N)cc1OC)c1ccccc1Br

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 2/20 0.34
AR P10275 2/20 0.34
CXCR1 P25024 1/20 0.34
ALDH1A1 P00352 3/20 0.33
LMNA P02545 2/20 0.33
IDH1 O75874 1/20 0.33
LRRK2 Q5S007 1/20 0.32
TRIM24 O15164 1/20 0.32
MAPT P10636 1/20 0.32
ACLY P53396 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
BRD4 O60885 1/20 0.32
BRD1 O95696 1/20 0.32
BRPF1 P55201 1/20 0.32
BRD9 Q9H8M2 1/20 0.32
BRPF3 Q9ULD4 1/20 0.32
PTGES2 Q9H7Z7 1/20 0.31
ALPL P05186 1/20 0.31
KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6931039 0.90 CXCR2 (0.38) CXCR2ARCXCR1ALDH1A1LMNA
SCHEMBL6930935 0.81 AR (0.37) CXCR2ARCXCR1IDH1LRRK2
SCHEMBL6930932 0.80 CXCR2 (0.38) CXCR2ARCXCR1ALDH1A1IDH1
SCHEMBL6930049 0.78 CXCR2 (0.48) CXCR2CXCR1ALDH1A1
SCHEMBL6930050 0.71 CXCR2 (0.44) CXCR2ARCXCR1ALDH1A1
SCHEMBL7067490 0.69 CXCR2 (0.48) CXCR2ARCXCR1ALDH1A1IDH1
SCHEMBL7097896 0.67 CXCR2 (0.45) CXCR2CXCR1ALDH1A1
SCHEMBL6129921 0.67 CXCR2 (0.47) CXCR2ARCXCR1ALDH1A1LMNA
SCHEMBL7067489 0.66 AR (0.42) CXCR2ARCXCR1ALDH1A1IDH1
SCHEMBL11798386 0.65 AR (0.47) ARALDH1A1LMNAMAPTBRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1265905-A4 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2003-03-12 EP disclosed
US-20030028042-A1 Il8-receptor antagonists SMITHKLINE BEECHAM CORPORATION 2003-02-06 US disclosed
EP-1265905-A1 IL-8 RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2002-12-18 EP disclosed
WO-2001064691-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2001-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030028042-A1 Il8-receptor antagonists CXCL8, CCR8, IL1RN CXCR2 28/4885AR 1177/4885CXCR1 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.